247 related articles for article (PubMed ID: 17347320)
1. The kinetics of inhibition of human acetylcholinesterase and butyrylcholinesterase by two series of novel carbamates.
Groner E; Ashani Y; Schorer-Apelbaum D; Sterling J; Herzig Y; Weinstock M
Mol Pharmacol; 2007 Jun; 71(6):1610-7. PubMed ID: 17347320
[TBL] [Abstract][Full Text] [Related]
2. Rational design of a drug for Alzheimer's disease with cholinesterase inhibitory and neuroprotective activity.
Weinstock M; Groner E
Chem Biol Interact; 2008 Sep; 175(1-3):216-21. PubMed ID: 18457821
[TBL] [Abstract][Full Text] [Related]
3. Enzyme-kinetic investigation of different sarin analogues reacting with human acetylcholinesterase and butyrylcholinesterase.
Bartling A; Worek F; Szinicz L; Thiermann H
Toxicology; 2007 Apr; 233(1-3):166-72. PubMed ID: 16904809
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and biological evaluation of conformationally restricted rivastigmine analogues.
Bolognesi ML; Bartolini M; Cavalli A; Andrisano V; Rosini M; Minarini A; Melchiorre C
J Med Chem; 2004 Nov; 47(24):5945-52. PubMed ID: 15537349
[TBL] [Abstract][Full Text] [Related]
5. N-alkylpiperidine carbamates as potential anti-Alzheimer's agents.
Košak U; Strašek N; Knez D; Jukič M; Žakelj S; Zahirović A; Pišlar A; Brazzolotto X; Nachon F; Kos J; Gobec S
Eur J Med Chem; 2020 Jul; 197():112282. PubMed ID: 32380361
[TBL] [Abstract][Full Text] [Related]
6. 6-Hydroxy- and 6-methoxy-beta-carbolines as acetyl- and butyrylcholinesterase inhibitors.
Schott Y; Decker M; Rommelspacher H; Lehmann J
Bioorg Med Chem Lett; 2006 Nov; 16(22):5840-3. PubMed ID: 16945529
[TBL] [Abstract][Full Text] [Related]
7. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
Youdim MB; Fridkin M; Zheng H
Mech Ageing Dev; 2005 Feb; 126(2):317-26. PubMed ID: 15621213
[TBL] [Abstract][Full Text] [Related]
8. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
Guay DR
Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
[TBL] [Abstract][Full Text] [Related]
9. Rivastigmine is a potent inhibitor of acetyl- and butyrylcholinesterase in Alzheimer's plaques and tangles.
Eskander MF; Nagykery NG; Leung EY; Khelghati B; Geula C
Brain Res; 2005 Oct; 1060(1-2):144-52. PubMed ID: 16212945
[TBL] [Abstract][Full Text] [Related]
10. Carbamates with differential mechanism of inhibition toward acetylcholinesterase and butyrylcholinesterase.
Darvesh S; Darvesh KV; McDonald RS; Mataija D; Walsh R; Mothana S; Lockridge O; Martin E
J Med Chem; 2008 Jul; 51(14):4200-12. PubMed ID: 18570368
[TBL] [Abstract][Full Text] [Related]
11. Acetylcholinesterase inhibitors: synthesis and structure-activity relationships of omega-[N-methyl-N-(3-alkylcarbamoyloxyphenyl)- methyl]aminoalkoxyheteroaryl derivatives.
Rampa A; Bisi A; Valenti P; Recanatini M; Cavalli A; Andrisano V; Cavrini V; Fin L; Buriani A; Giusti P
J Med Chem; 1998 Oct; 41(21):3976-86. PubMed ID: 9767635
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K
Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease.
Bolea I; Juárez-Jiménez J; de Los Ríos C; Chioua M; Pouplana R; Luque FJ; Unzeta M; Marco-Contelles J; Samadi A
J Med Chem; 2011 Dec; 54(24):8251-70. PubMed ID: 22023459
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, in vitro assay, and molecular modeling of new piperidine derivatives having dual inhibitory potency against acetylcholinesterase and Abeta1-42 aggregation for Alzheimer's disease therapeutics.
Kwon YE; Park JY; No KT; Shin JH; Lee SK; Eun JS; Yang JH; Shin TY; Kim DK; Chae BS; Leem JY; Kim KH
Bioorg Med Chem; 2007 Oct; 15(20):6596-607. PubMed ID: 17681794
[TBL] [Abstract][Full Text] [Related]
15. Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease.
Sterling J; Herzig Y; Goren T; Finkelstein N; Lerner D; Goldenberg W; Miskolczi I; Molnar S; Rantal F; Tamas T; Toth G; Zagyva A; Zekany A; Finberg J; Lavian G; Gross A; Friedman R; Razin M; Huang W; Krais B; Chorev M; Youdim MB; Weinstock M
J Med Chem; 2002 Nov; 45(24):5260-79. PubMed ID: 12431053
[TBL] [Abstract][Full Text] [Related]
16. Microcalorimetric study of the inhibition of butyrylcholinesterase by carbamates.
Debord J; Laubarie C; Dantoine T
Anal Biochem; 2008 Feb; 373(2):247-52. PubMed ID: 17950687
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and in vitro evaluation of N-alkyl-7-methoxytacrine hydrochlorides as potential cholinesterase inhibitors in Alzheimer disease.
Korabecny J; Musilek K; Holas O; Binder J; Zemek F; Marek J; Pohanka M; Opletalova V; Dohnal V; Kuca K
Bioorg Med Chem Lett; 2010 Oct; 20(20):6093-5. PubMed ID: 20817518
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, structural characterization, docking, lipophilicity and cytotoxicity of 1-[(1R)-1-(6-fluoro-1,3-benzothiazol-2-yl)ethyl]-3-alkyl carbamates, novel acetylcholinesterase and butyrylcholinesterase pseudo-irreversible inhibitors.
Pejchal V; Štěpánková Š; Pejchalová M; Královec K; Havelek R; Růžičková Z; Ajani H; Lo R; Lepšík M
Bioorg Med Chem; 2016 Apr; 24(7):1560-72. PubMed ID: 26947959
[TBL] [Abstract][Full Text] [Related]
19. Sensitivity of butyrylcholinesterase knockout mice to (--)-huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer's disease drugs and indicates butyrylcholinesterase function in neurotransmission.
Duysen EG; Li B; Darvesh S; Lockridge O
Toxicology; 2007 Apr; 233(1-3):60-9. PubMed ID: 17194517
[TBL] [Abstract][Full Text] [Related]
20. A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer's disease.
Lu C; Zhou Q; Yan J; Du Z; Huang L; Li X
Eur J Med Chem; 2013 Apr; 62():745-53. PubMed ID: 23454517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
